Open AccessLeaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020
Author(s) -
Neha K. Prasad,
Ian B. Seiple,
Ryan T. Cirz,
Oren S. Rosenberg
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00054-22
Subject(s) - antibiotics , medicine , intensive care medicine , drug development , food and drug administration , clinical microbiology , clinical research , clinical trial , drug , risk analysis (engineering) , biology , pharmacology , microbiology and biotechnology
The World Health Organization (WHO) has warned that our current arsenal of antibiotics is not innovative enough to face impending infectious diseases, especially those caused by multidrug-resistant Gram-negative pathogens. Although the current preclinical pipeline is well stocked with novel candidates, the last U.S.